secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001193125-25-117809
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharma Q1 net loss narrows to $34.3M; cash $425M; Phase 3 HCV trial enrolling
--------------------------------------------------------------------------------

- Net loss $34.3M ($0.40/share) vs $63.2M ($0.75) in Q1 2024; R&D expense down 49% to $29.6M.
- Cash, equivalents and marketable securities $425.4M at March 31, down from $454.7M at Dec 31.
- Phase 3 C-BEYOND HCV trial enrolling; second Phase 3 C-FORWARD expected mid-2025.
- Strategic alternatives review with Evercore ongoing; workforce reduced ~25% to save ~$15M through 2027.
- Board authorized $25M share repurchase; Arthur Kirsch and Howard Berman appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/0001193125-25-117809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/d923851d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-117809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer